EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma

Chloe O'Neill iD, Marloes E C Broekmans, Charlotte L B M Korst iD, Maria Krevvata, Giada Dal Collo, Richard W Groen, Bing Li, Serena R Baglio iD, Ulrike Philippar, Kodandaram Pillarisetti, Sonja Zweegman, Deeksha Vishwamitra und 2 weitere

HemaSphere · 2026-10 · 10 (10)

DOI: 10.1002/hem3.70487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 07.10.2026. Verfasst von Chloe O'Neill und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Cancer Center Amsterdam Amsterdam UMC, Vrije Universiteit Amsterdam Amsterdam The Netherlands. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Johnson and Johnson.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in terms of bispecific antibodies (BsAbs) targeting single tumor‐associated antigens in multiple myeloma (MM), not all patients respond, and most eventually relapse. Using flow cytometry, we found that BCMA and GPRC5D expression is highly heterogeneous within and between patients. Dual targeting with ramantamig (JNJ‐79635322), a trispecific antibody targeting both BCMA and GPRC5D on the tumor cell surface, has been hypothesized to improve efficacy by overcoming heterogeneous target expression and preventing resistance due to antigen escape. Using T‐cells from healthy donors, ramantamig was significantly more effective than mono‐targeting antibodies against BCMA + GPRC5D + MM cell lines, and also efficiently eliminated single antigen‐positive MM cell lines. Additionally, ramantamig effectively induced MM cell lysis in 32 BM samples from MM patients (mean lysis with 0.4 nM: 60%), demonstrating superior cytotoxic activity compared to BCMA‐ and GPRC5D‐mono‐targeting BsAbs (13% and 5%, respectively). There was no difference in ramantamig‐mediated lysis of MM cells from newly diagnosed or heavily pretreated, BsAb‐naïve patients. Importantly, tumor cell target expression was an important determinant of ex vivo response, shown by superior MM cell lysis in samples with higher than median baseline proportion of GPRC5D/BCMA double‐antigen‐positive MM cells, when compared to lower GPRC5D/BCMA expression. Notably, ramantamig potency was less affected by the presence of soluble BCMA, compared to the BCMA‐mono‐targeting control antibody. Finally, ramantamig showed superior potency, compared to the combination of two single‐targeted BsAbs, probably due to higher avidity against heterogeneous targets. In conclusion, dual‐antigen targeting with ramantamig represents a significant advancement in overcoming tumor heterogeneity and preventing antigen escape‐mediated resistance.

Autor:innen und Institutionen

  • Department of Hematology, Cancer Center Amsterdam Amsterdam UMC, Vrije Universiteit Amsterdam Amsterdam The Netherlands.
  • Johnson&Johnson Spring House Pennsylvania United States.
  • Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
  • Johnson&Johnson Beerse Belgium.

ORCID-Profile: Chloe O'Neill, Charlotte L B M Korst, Serena R Baglio, Tuna Mutis, Niels W C J van de Donk

Förderung

  • Johnson and Johnson

Zitieren

APA

O'Neill, C., Broekmans, M. E. C., Korst, C. L. B. M., Krevvata, M., Dal Collo, G., Groen, R. W., Li, B., Baglio, S. R., Philippar, U., Pillarisetti, K., Zweegman, S., Vishwamitra, D., Mutis, T., & van de Donk, N. W. C. J. (2026). Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70487

Vancouver

O'Neill C, Broekmans MEC, Korst CLBM, Krevvata M, Dal Collo G, Groen RW, et al. Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma. HemaSphere. 2026;10(10). doi:10.1002/hem3.70487

BibTeX
@article{ONeill2026,
  author = {O'Neill, Chloe and Broekmans, Marloes E C and Korst, Charlotte L B M and Krevvata, Maria and Dal Collo, Giada and Groen, Richard W and Li, Bing and Baglio, Serena R and Philippar, Ulrike and Pillarisetti, Kodandaram and Zweegman, Sonja and Vishwamitra, Deeksha and Mutis, Tuna and van de Donk, Niels W C J},
  title = {Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {10},
  doi = {10.1002/hem3.70487}
}
Kostenlos starten →